Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 2/2013

01.06.2013 | short review

Endpoints in lung cancer trials: today’s challenges for clinical statistics

verfasst von: Dipl.Math Lothar R Pilz, Prof. Dr. med Christian Manegold

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

The identification of potential molecular targets in lung cancer has stimulated the today’s search for antitumor agents to be tested in clinical trials with an appropriate endpoint. Three main categories of classical endpoints are applied: survival time endpoints, symptom endpoints, and endpoints relying on patients’ reporting, with the gold standard overall survival (OS). Efforts have been taken to substitute OS by surrogates. As a surrogate for OS, progression-free survival (PFS) should have the inherent considerable advantage, that it can detect subpopulations with longer PFS intervals early. OS and PFS was linked directly by splitting OS into PFS and the rest as survival time past progression (SPP). Variation in SPP is a quantitative factor in validating PFS as a surrogate of OS. If accompanied by some independent measures like quality of life (QoL) or treatment toxicity, PFS should be able to cover the clinical benefit achieved by treatment. In an adaptive trial design, the impact of SPP can be modeled by adjustments of the covariate structure by factors as QoL. OS as the gold standard is easy to measure and is precise but results are available late. PFS in contrast is complex to measure but will become attractive, because its results are available earlier and are not influenced by subsequent therapies. Therefore, PFS, as an endpoint with some extra measures, has become an acceptable alternative to OS in lung cancer trials recently. Extra measures under discussion to enrich PFS are QoL and information of SPP, or adaptive designs.
Literatur
1.
Zurück zum Zitat Pilz LR, Manegold C, Schmid-Bindert G. Statistical considerations and endpoints for clinical lung cancer studies: can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small cell lung cancer? Transl Lung Cancer Res. 2012;1(1):26–35. Pilz LR, Manegold C, Schmid-Bindert G. Statistical considerations and endpoints for clinical lung cancer studies: can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small cell lung cancer? Transl Lung Cancer Res. 2012;1(1):26–35.
2.
Zurück zum Zitat Klein PJ, Goel PK (eds.). Survival analysis: State of the art. Dordrecht: Kluwer Academic Publisher; 1992. Klein PJ, Goel PK (eds.). Survival analysis: State of the art. Dordrecht: Kluwer Academic Publisher; 1992.
3.
Zurück zum Zitat Klein PJ, Moeschberger ML. Survival analysis. Techniques for censored and truncated data. 2nd ed. New York: Springer-Verlag; 2003. Klein PJ, Moeschberger ML. Survival analysis. Techniques for censored and truncated data. 2nd ed. New York: Springer-Verlag; 2003.
4.
Zurück zum Zitat Rosenberger WF, Lachin JM. Randomization in clinical trials: Theory and practice. New York: John Wiley & Sons; 2002.CrossRef Rosenberger WF, Lachin JM. Randomization in clinical trials: Theory and practice. New York: John Wiley & Sons; 2002.CrossRef
5.
Zurück zum Zitat Day SJ, Altman DG. Statistics notes: blinding in clinical trials and other studies. Brit Med J. 2000;321(7259):504.PubMedCrossRef Day SJ, Altman DG. Statistics notes: blinding in clinical trials and other studies. Brit Med J. 2000;321(7259):504.PubMedCrossRef
6.
Zurück zum Zitat Schulz KF, Grimes DA. Blinding in randomized trials: hiding who got what. Lancet. 2002;359(9307):696–700.PubMedCrossRef Schulz KF, Grimes DA. Blinding in randomized trials: hiding who got what. Lancet. 2002;359(9307):696–700.PubMedCrossRef
7.
Zurück zum Zitat Shih WJ. Problems in dealing with missing data and informative censoring in clinical trials. Curr Control Trials Cardiovasc Med. 2002;3:4. doi: 10.1186/1468-6708-3-4. Shih WJ. Problems in dealing with missing data and informative censoring in clinical trials. Curr Control Trials Cardiovasc Med. 2002;3:4. doi: 10.1186/1468-6708-3-4.
8.
Zurück zum Zitat Michiels S, Mauguen A, Fisher D, et al. Evaluation of disease-free survival as surrogate endpoint for overall survival using two individual patient data meta-analyses of adjuvant chemotherapy in operable non-small cell lung cancer. J Clin Oncol. 2011;29(No 15_suppl):abstract 7004. Michiels S, Mauguen A, Fisher D, et al. Evaluation of disease-free survival as surrogate endpoint for overall survival using two individual patient data meta-analyses of adjuvant chemotherapy in operable non-small cell lung cancer. J Clin Oncol. 2011;29(No 15_suppl):abstract 7004.
9.
Zurück zum Zitat Guidance for Industry Clinical Trial Endpoints for the Approval of Non-Small Cell Lung Cancer Drugs and Biologics. Draft Guidance. June 2011. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM259421.pdf Guidance for Industry Clinical Trial Endpoints for the Approval of Non-Small Cell Lung Cancer Drugs and Biologics. Draft Guidance. June 2011. http://​www.​fda.​gov/​downloads/​Drugs/​GuidanceComplian​ceRegulatoryInfo​rmation/​Guidances/​UCM259421.​pdf
10.
Zurück zum Zitat George SL. Response rate as an endpoint in clinical trials. Editorial. J Natl Cancer Inst. 2007;99(2):98–9.PubMedCrossRef George SL. Response rate as an endpoint in clinical trials. Editorial. J Natl Cancer Inst. 2007;99(2):98–9.PubMedCrossRef
11.
Zurück zum Zitat Freemantle N, Calvert M. Composite and surrogate outcomes in randomized controlled trials. Editorial. British Med J. 2007;334(7597):756–7.CrossRef Freemantle N, Calvert M. Composite and surrogate outcomes in randomized controlled trials. Editorial. British Med J. 2007;334(7597):756–7.CrossRef
12.
Zurück zum Zitat Thongprasert S, Sanguanmitra P, Juthapan W, Clinch J. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer. 1999;24(1):17–24.PubMedCrossRef Thongprasert S, Sanguanmitra P, Juthapan W, Clinch J. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer. 1999;24(1):17–24.PubMedCrossRef
13.
Zurück zum Zitat Patient-Reported Outcome Measurement Group, Oxford. A structured review of patient-oriented outcome measures (PROMs) for lung cancer. Report to the department of health, 2010, University of Oxford. Patient-Reported Outcome Measurement Group, Oxford. A structured review of patient-oriented outcome measures (PROMs) for lung cancer. Report to the department of health, 2010, University of Oxford.
14.
Zurück zum Zitat Johnson KR, Ringland C, Stokes BJ, et al. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. Lancet Oncol. 2006;7(9):741–6.PubMedCrossRef Johnson KR, Ringland C, Stokes BJ, et al. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. Lancet Oncol. 2006;7(9):741–6.PubMedCrossRef
15.
Zurück zum Zitat Soria JC, Massard C, Le Chevalier T. Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? Ann Oncol. 2010;21(12):2324–32.PubMedCrossRef Soria JC, Massard C, Le Chevalier T. Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? Ann Oncol. 2010;21(12):2324–32.PubMedCrossRef
16.
Zurück zum Zitat Lin DY, Robins JM, Wei LJ. Comparing two failure time distributions in the presence of dependent censoring. Biometrika. 1996;83(2):381–93.CrossRef Lin DY, Robins JM, Wei LJ. Comparing two failure time distributions in the presence of dependent censoring. Biometrika. 1996;83(2):381–93.CrossRef
17.
Zurück zum Zitat Chen TT, Simon RM, Korn EL, et al. Investigation of disease-free survival as a surrogate endpoint for survival in cancer clinical trials. Commun Statist Theory Meth. 1998;27(6):1363–78.CrossRef Chen TT, Simon RM, Korn EL, et al. Investigation of disease-free survival as a surrogate endpoint for survival in cancer clinical trials. Commun Statist Theory Meth. 1998;27(6):1363–78.CrossRef
18.
Zurück zum Zitat Ulm K. Primary endpoints in cancer trials. J Thorac Dis. 2011;3(2):82–3.PubMed Ulm K. Primary endpoints in cancer trials. J Thorac Dis. 2011;3(2):82–3.PubMed
19.
Zurück zum Zitat Malik SM, Ibrahim A, Sridhara R, Justice RL, Pazdur R. Use of progression-free survival (PFS) as an endpoint in advanced non-small cell lung cancer (NSCLC) trials: FDA perspective. J Clin Oncol. 2010;28(suppl;abstr.e18001). Malik SM, Ibrahim A, Sridhara R, Justice RL, Pazdur R. Use of progression-free survival (PFS) as an endpoint in advanced non-small cell lung cancer (NSCLC) trials: FDA perspective. J Clin Oncol. 2010;28(suppl;abstr.e18001).
20.
Zurück zum Zitat Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression free survival. J Natl Cancer Inst. 2009;101(23):1642–9.PubMedCrossRef Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression free survival. J Natl Cancer Inst. 2009;101(23):1642–9.PubMedCrossRef
21.
Zurück zum Zitat Bowater RJ, Bridge LJ, Lilford RJ. The relationship between progression free and post-progression survival in treating four types of metastatic cancer. Cancer Letter 2008;262(1):48–53.CrossRef Bowater RJ, Bridge LJ, Lilford RJ. The relationship between progression free and post-progression survival in treating four types of metastatic cancer. Cancer Letter 2008;262(1):48–53.CrossRef
22.
Zurück zum Zitat Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for non-squamous non-small cell lung cancer: results from a randomized phase III trial (AVAiL). Ann Oncol. 2010;21(9):1804–09.PubMedCrossRef Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for non-squamous non-small cell lung cancer: results from a randomized phase III trial (AVAiL). Ann Oncol. 2010;21(9):1804–09.PubMedCrossRef
23.
Zurück zum Zitat Hotta K, Suzuki E, Di Maio M, et al. Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer. Lung Cancer. 2013;79(1):20–6.PubMedCrossRef Hotta K, Suzuki E, Di Maio M, et al. Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer. Lung Cancer. 2013;79(1):20–6.PubMedCrossRef
24.
Zurück zum Zitat Zietemann VD, Schuster T, Duell THG. Post-study therapy as a source of confounding in survival analysis of first-line studies in patients with advanced non-small-cell lung cancer. J Thorac Dis. 2011;3(2):88–98.PubMed Zietemann VD, Schuster T, Duell THG. Post-study therapy as a source of confounding in survival analysis of first-line studies in patients with advanced non-small-cell lung cancer. J Thorac Dis. 2011;3(2):88–98.PubMed
25.
Zurück zum Zitat Hilbe W, Aigner K, Dittrich C, et al. Expertenempfehlung 2006 zur rationalen Zweitlinien-Therapie beim nicht-kleinzelligen Bronchuskarzinom. Wien Klin Wochenschr. 2007;119(7–8):259–66.PubMedCrossRef Hilbe W, Aigner K, Dittrich C, et al. Expertenempfehlung 2006 zur rationalen Zweitlinien-Therapie beim nicht-kleinzelligen Bronchuskarzinom. Wien Klin Wochenschr. 2007;119(7–8):259–66.PubMedCrossRef
26.
Zurück zum Zitat Fleming TR, Rothmann MD, Lu H-L. Issues in using progression-free survival when evaluating oncology products. J Clin Oncol. 2009;27(17):2874–80.PubMedCrossRef Fleming TR, Rothmann MD, Lu H-L. Issues in using progression-free survival when evaluating oncology products. J Clin Oncol. 2009;27(17):2874–80.PubMedCrossRef
27.
Zurück zum Zitat Johnson JR, Williams G, Pazdur R. End points and United Stated Food and Drug Administration approval of oncology drugs. J Clin Oncol. 2003;21(7):1404–11.PubMedCrossRef Johnson JR, Williams G, Pazdur R. End points and United Stated Food and Drug Administration approval of oncology drugs. J Clin Oncol. 2003;21(7):1404–11.PubMedCrossRef
28.
Zurück zum Zitat Fleming TR, DeMets DL. Surrogate end points in clinical trials: Are we being misled? Ann Intern Med. 1996;125(7):605–13. Fleming TR, DeMets DL. Surrogate end points in clinical trials: Are we being misled? Ann Intern Med. 1996;125(7):605–13.
29.
Zurück zum Zitat Hotta K, Kiura K, Fujiwara Y, et al. Role of survival post-progression in Phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review. PLoS ONE. 2011;6(11):e26646. Hotta K, Kiura K, Fujiwara Y, et al. Role of survival post-progression in Phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review. PLoS ONE. 2011;6(11):e26646.
30.
Zurück zum Zitat Hayashi H, Okamoto I, Morita S, Taguri M, Nakagawa K. Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer. Ann Oncol. 2012;23(6):1537–1541.PubMedCrossRef Hayashi H, Okamoto I, Morita S, Taguri M, Nakagawa K. Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer. Ann Oncol. 2012;23(6):1537–1541.PubMedCrossRef
31.
Zurück zum Zitat Reck M. Quality of life as endpoint of clinical trials. Lung Cancer. 2009; 64suppl1 (43IN):S22–S23. Reck M. Quality of life as endpoint of clinical trials. Lung Cancer. 2009; 64suppl1 (43IN):S22–S23.
32.
Zurück zum Zitat Tassinari D. Surrogate end points of quality of life assessment: have we really found what we are looking for? Health Qual of Life Outcomes. 2003;1:71.CrossRef Tassinari D. Surrogate end points of quality of life assessment: have we really found what we are looking for? Health Qual of Life Outcomes. 2003;1:71.CrossRef
33.
Zurück zum Zitat Freemantle N, Calvert M. Composite and surrogate outcomes in randomized controlled trials. Editorial. British Med J. 2007;334(7597):756–7.CrossRef Freemantle N, Calvert M. Composite and surrogate outcomes in randomized controlled trials. Editorial. British Med J. 2007;334(7597):756–7.CrossRef
34.
Zurück zum Zitat Schrimpf D, Manegold C, Pilz LR. Design of clinical studies: adaptive randomization and progression-free survival (PFS) as an endpoint in clinical studies of advanced non-small cell lung cancer (NSCLC). Int J Clin Pharmaceutical Therapeutics. 2013;51(1):84–6. Schrimpf D, Manegold C, Pilz LR. Design of clinical studies: adaptive randomization and progression-free survival (PFS) as an endpoint in clinical studies of advanced non-small cell lung cancer (NSCLC). Int J Clin Pharmaceutical Therapeutics. 2013;51(1):84–6.
Metadaten
Titel
Endpoints in lung cancer trials: today’s challenges for clinical statistics
verfasst von
Dipl.Math Lothar R Pilz
Prof. Dr. med Christian Manegold
Publikationsdatum
01.06.2013
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2013
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-013-0082-z

Weitere Artikel der Ausgabe 2/2013

memo - Magazine of European Medical Oncology 2/2013 Zur Ausgabe